A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T ...

Chimeric antigen receptor T-cell therapy conferred sustained benefit to individuals with high-risk smoldering multiple myeloma, according to phase 2 trial results. All patients who received a single ...

The medical community is now utilizing minimal residual disease (MRD) testing, which can detect a single cancer cell among a ...

Researchers are advancing in vivo CAR-T cell engineering, which generates therapeutic immune cells directly inside patients, bypassing complex lab manufacturing. This approach could broaden access, ...

Eli Lilly's $7 billion deal for Kelonia Therapeutics on Monday was just the latest example | Despite the recent “feeding ...

MSCs improve therapeutic consistency and precision across cell therapies. The approach also supports scalable allogeneic ...

Legend Biotech Corporation looks like a J&J acquisition target as Carvykti sales surge and Phase 2 data impress. Click for ...

CAR-T cell therapy has transformed treatment for certain cancers by engineering a patient’s immune cells to identify and ...

Century Therapeutics (IPSC) analysis: autoimmune CAR-cell pivot, CNTY-813 Type 1 diabetes upside, cash burn cuts, rNPV fair ...

NEW YORK – Create Medicines has started clinically testing an in vivo CAR therapy that comprises a cancer-killing medley of T, NK, and myeloid cells.

The treatment, developed by Regeneron Pharmaceuticals, is for a very rare form of deafness. But it represents a medical ...

BMW just pulled the wraps off its facelifted 7 Series at the 2026 Beijing Auto Show, and if you were expecting a mild ...